CD274 and plasma cell myeloma: In this sense, lenalidomide has been reported to reduce PD-L1 expression on RPMI-8226 and primary MM cells, and the combination of lenalidomide and pidilizumab (anti-PD-1) significantly enhanced NK-cell cytotoxicity against myeloma cells [35].